Why the study?
Does continuing thienopyridine for 30 months compared to 12 months reduce stent thrombosis and MACCE in patients with bare metal or drug-eluting stents taking aspirin?
Does continuing thienopyridine for 30 months compared to 12 months reduce stent thrombosis and MACCE in patients with bare metal or drug-eluting stents taking aspirin?
Extending dual antiplatelet therapy from 12 to 30 months reduces ischemic events but increases bleeding in the overall stent population, though the benefit was not statistically significant in the underpowered bare metal stent subset.
No takes yet. Share an insight, caveat, or question.
Supports extending DAPT to 30 months post-stenting; extends RCT evidence on ischemic benefit versus bleeding trade-off.
Kereiakes et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: